Baxter International Inc (BAX) Director Carole J. Shapazian Sells 11,749 Shares
Baxter International Inc (NYSE:BAX) Director Carole J. Shapazian sold 11,749 shares of the business’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $68.48, for a total transaction of $804,571.52. Following the completion of the sale, the director now owns 15,237 shares in the company, valued at $1,043,429.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
NYSE:BAX traded down $0.47 on Thursday, reaching $66.79. The stock had a trading volume of 4,274,141 shares, compared to its average volume of 3,267,339. The firm has a market cap of $35.79 billion, a price-to-earnings ratio of 26.93, a price-to-earnings-growth ratio of 1.81 and a beta of 1.04. The company has a current ratio of 2.60, a quick ratio of 1.96 and a debt-to-equity ratio of 0.38. Baxter International Inc has a 12-month low of $61.05 and a 12-month high of $78.38.
Baxter International (NYSE:BAX) last released its earnings results on Wednesday, October 31st. The medical instruments supplier reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.06. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.79 billion. Baxter International had a net margin of 10.90% and a return on equity of 17.67%. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.64 EPS. On average, equities research analysts forecast that Baxter International Inc will post 3 earnings per share for the current fiscal year.
Baxter International declared that its board has initiated a share buyback plan on Tuesday, November 13th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 6.1% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.
A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Baxter International by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 36,398,931 shares of the medical instruments supplier’s stock valued at $2,805,993,000 after purchasing an additional 470,198 shares in the last quarter. FMR LLC lifted its holdings in Baxter International by 2.5% in the 3rd quarter. FMR LLC now owns 29,356,040 shares of the medical instruments supplier’s stock valued at $2,263,057,000 after purchasing an additional 719,013 shares in the last quarter. Morgan Stanley increased its stake in shares of Baxter International by 267.9% during the 3rd quarter. Morgan Stanley now owns 10,570,520 shares of the medical instruments supplier’s stock valued at $814,880,000 after acquiring an additional 7,697,267 shares during the last quarter. Standard Life Aberdeen plc increased its stake in shares of Baxter International by 121.2% during the 3rd quarter. Standard Life Aberdeen plc now owns 5,743,738 shares of the medical instruments supplier’s stock valued at $442,813,000 after acquiring an additional 3,146,868 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Baxter International by 7.6% during the 3rd quarter. Janus Henderson Group PLC now owns 4,321,125 shares of the medical instruments supplier’s stock valued at $333,116,000 after acquiring an additional 306,714 shares during the last quarter. Institutional investors own 83.40% of the company’s stock.
Several equities research analysts recently commented on the stock. Zacks Investment Research reiterated a “hold” rating and issued a $71.00 price objective on shares of Baxter International in a research report on Monday, November 12th. Piper Jaffray Companies decreased their price objective on shares of Baxter International from $83.00 to $72.00 and set an “overweight” rating on the stock in a research report on Thursday, November 1st. ValuEngine upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a research report on Thursday, November 15th. BMO Capital Markets decreased their price objective on shares of Baxter International from $86.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday, November 1st. Finally, Citigroup decreased their price objective on shares of Baxter International from $76.00 to $69.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 13th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $74.41.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/baxter-international-inc-bax-director-carole-j-shapazian-sells-11749-shares/2665792.html.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Article: Return on Equity (ROE)
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.